Rapport Therapeutics, founded in 2023 through a collaboration between Third Rock Ventures and Johnson & Johnson, is developing a potential first-of-its-kind epilepsy medication called “RAP-219.” The company recently initiated late-stage trials specifically targeting a type of seizure, focusing on the TARPγ8 protein, which is believed to modulate AMPA receptors in the brain, potentially controlling seizures while minimizing side effects.
CEO Abraham Ceesay expressed confidence in their approach, citing promising Phase 2 results that showed a 78% reduction in clinical seizure frequency. The company aims to independently market RAP-219, believing that the unique nature of neuroscience allows smaller biotech firms to succeed commercially. Ceesay also emphasized the importance of strategic partnerships and intentional capital allocation as they plan for future growth and development.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biopharmadive.com/news/Rapport-Ceesay-seizure-epilepsy-drug-neuroscience-biotech-product-launch/822809/
